Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., Gefen, N., Izraeli, S., Rechavi, G., Pass, H., Nonaka, D., Li, J., Spector, Y., Rosenfeld, N., Chajut, A., Cohen, D., Aharonov, R. and Mansukhani, M. (2009) Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous from Nonsquamous Non-Small-Cell Lung Carcinoma. Journal of Clinical Oncology, 27, 2030-2037. http://dx.doi.org/10.1200/JCO.2008.19.4134

has been cited by the following article:

• TITLE: Prognostic Role of miR-205 in Early-Stage (T1N0) Non-Small Cell Lung Cancer

  AUTHORS: Laura Boldrini, Mirella Giordano, Adele Servadio, Greta Alì, Alice Cocco, Marco Lucchi, Pietro Bertoglio, Franca Melfi, Alfredo Mussi, Gabriella Fontanini

  KEYWORDS: Non-Small Cell Lung Cancer, miR-21, let-7g, miR-205, Prognosis

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.2, June 20, 2014

  ABSTRACT: Background: Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of miRNA let-7, miR-21, and miR-205 are inconclusive. The aim of the present analysis was therefore to evaluate the expression and the prognostic role of the above mentioned miRNAsin early-stage(T1N0) NSCLC patients. Methods: Quantification of let-7g, miR-21, and miR-205 expression was carried out into 105 early-stage NSCLC by quantitative Real Time-PCR (qRT-PCR).Results: a significant association between the low miR-205 expression and ADC histotype (p0.0001) compared to SCCwas found; moreover, survival analysis showed thattumors with a highmiR-205 expression had a significantly shorter mean PFS and OS compared to the patients with a low expression of this miRNA (p = 0.02 and p = 0.03, respectively). No other statistically significant correlations were observed between the analysed miRNAs and the main clinico-pathological characteristics of the NSCLC patients. Conclusion: The results indicated that miR-205 could represent a useful marker in the prognostic management of the early-stage (T1N0) NSCLC patients.